Specificity of transaminase activities in the prediction of drug-induced hepatotoxicity

• Published in: Journal of toxicological sciences 2020, Vol.45(9), pp.515-537
• Main Authors: Kobayashi, Akio, Suzuki, Yusuke, Sugai, Shoichiro
• Format: Article
• Language: English
• Subjects: Alanine; Alanine aminotransferase; Alanine transaminase; Aspartate aminotransferase; Biomarker; Biomarkers; Blood; Blood levels; Drug-induced liver injury; Drugs; Gluconeogenesis; Glucose metabolism; Glucosidase; Glycolysis; Hepatotoxicity; Lipid metabolism; Lipids; Liver; Organs; Pharmacology; Toxicity; Transaminase; Transaminases; α-Glucosidase
• ISSN: 0388-1350; 1880-3989
• DOI: 10.2131/jts.45.515

The activities of the transaminases (aminotransferases) alanine aminotransferase and aspartate aminotransferase in the blood (serum or plasma) are widely used as sensitive markers of possible tissue damage and, in particular for liver toxicity. On the other hand, an increase in transaminase activities is not always accompanied by findings suggestive of hepatotoxicity. Transaminases are some of the key enzymes in the gluconeogenesis and glycolysis pathways and exist in many organs and tissues which have high activities of the gluconeogenesis and glycolysis. The activities of transaminases are altered not only in the liver but also in other organs by modification of gluconeogenesis by nutritional or hormonal factors and this phenomenon leads to alteration of transaminase activity in the blood. Drugs, which are considered to directly or secondarily modify gluconeogenesis through lowering blood glucose levels or activating lipid metabolism, such as α-glucosidase inhibitors and fibrates, slightly increase transaminase activities in the blood but there is little evidence that the phenomenon is related to drug-induced liver injury (DILI). This type of elevations can be called pharmacology-related elevation. The pharmacology-related elevation of transaminase activities sometimes makes it difficult to assess precisely the potential hepatotoxicity of new investigational drugs. Considering the characteristic of transaminases, concomitant use of new biomarkers more specific to hepatic injury is needed in the assessment of DILI both in non-clinical and clinical studies. In this review, we will discuss the specificity of transaminases to DILI and future perspectives for transaminases in the estimation of risk of DILI.